Ending Childhood Needle Trauma Starts With Better Injection Technology
Millions of children develop lifelong needle fear from routine injections.
Biopreme's Effi-Q is a patented negative-pressure stabilized injection adapter designed to reduce pain, fear, and procedural variability—beginning with pediatrics and expandable across all subcutaneous injection care.
For Millions of Children, Their First Medical Trauma Is a Routine Injection
Needle pain is the single largest source of pain experienced by children in healthcare. Early painful injection experiences are strongly associated with the development of needle fear and phobia, beginning in early childhood and persisting into adulthood.
What appears to be a brief moment of discomfort can shape a child’s relationship with healthcare for life.
of children born after 2000 fear needles
adults who trace needle phobia to childhood
refuse vaccines due to fear of needle pain
years since last innovation in injection devices
The Negative Outcome
Needle Fear Grows Into Healthcare Avoidance
Adults who fear needles are more likely to delay or refuse vaccinations, blood tests, and prescribed medical therapeutics. Many trace that fear back to childhood injection experiences.
Reducing pediatric injection pain isn’t just compassionate, it’s preventive medicine.
The Problem
In Over 100 Years of Medical Device Innovation, Injection Technology Has Barely Evolved
Despite advances across nearly every medical device category, subcutaneous injection technique still relies on manual “pinch and jab” methods with all its inherent problems:
No regulated penetration depth
No injection site stabilization
High dependence on technique
Draconian esthetics that engender fear
The Technology
Negative-Pressure Stabilization Changes the Physics of Injection
Biopreme’s patented adapter, Effi-Q, applies gentle negative pressure to stabilize tissue and control penetration depth while concealing the needle.
Instead of relying on manual technique, Effi-Q introduces a mechanically guided injection environment designed to make injections more consistent and efficacious, and less traumatic.
Fixed 3mm penetration depth ensures accuracy & consistency
Strategy experience and analytical expertise combine to enable decision making and create value.
Negative-pressure to tissue eases pain & stabilizes site
Applying negative pressure numbs the site and gently brings the tissue to the needle rather than forcing the needle into the sitel
Needle concealment removes visual flinch triggers
Many patients, adults and children alike, instinctively flinch upon sight of the needle. Effi-Q obscures the visual, maintaining calm.
Skirt reduces blood/drug exposure risk for clinicians
Needle sticks happen more often than we'd like to admit. Effi-Q is designed to protect both patient and clinician from needle injury.
Compatible with standard syringes
Effi-Q is needle agnostic so no supply chain or clinical processes are disrupted nor is your choice of needle hampered in any way.
Aids in perfusion of vaccine or medication administered
Effi-Q allows for the most accurate and optimal depth, promoting efficient perfusion optimal absorption and minimal after pain.
The Team
Designed by a Harvard Trained Physician, Developed by Community
From a renowned physician in Russia, to a celebrity doctor in the US and a tiny coastal town in British Columbia, Canada, Biopreme's Effi-Q has captured the hearts, minds, and support of clinicians, medical device professionals, and concerned parents, worldwide.
An Early News Feature
Douglas Magazine
July 2018
Developing a device to lessen childhood pain was bound to attract attention. As we were in the early stages of development our efforts caught the eye of a local business magazine and our little corner of the world got its first glimpse of our Effi-Q device.
Since then we've taken some time to talk to clinicians and parents to get their feedback and make sure we're on the right track. We also spoke, and collaborated with, seasoned professionals in the business and medical device community to better understand our options for next steps and determine the best approach to getting this to the patients that need it the most - children, the elderly, and vulnerable patient populations.